It was worth pointing out that such studies claimed synergistic effect between BRAF inhibitors and EZH2 inhibitors in a subset of cancers that had EZH2 amplification or gain-of-function mutations which led to re-distribution of H3K27me3 [44]. This evidence concerns the gene EZH2 and cancer.